Psicofármacos y apnea de sueño en pacientes internados en salas del Hospital Pasteur-2019.

Abstract

Se realizó un estudio descriptivo observacional, de corte transversal, con el objetivo de identificar la asociación del consumo de psicofármacos y el aumento del riesgo de padecer apnea obstructiva del sueño (AOS), en pacientes internados y bajo tratamiento con psicofármacos en el Hospital Pasteur durante el periodo julio-septiembre de 2019. Mediante instrumento de tamizaje el cuestionario STOP BANG, se halló riesgo elevado de AOS en el 59,4% de la muestra, del cual 75,6% corresponde al sexo masculino y el 24,4% corresponde al sexo femenino. El riesgo elevado para AOS fue de 54,3% con un solo psicofármaco y 71,4% con dos. Dentro de los psicofármacos, el grupo de antipsicóticos fue el que se asoció con mayor frecuencia al riesgo elevado de AOS.

A cross-sectional study was conducted with the objective of identifying the link between psychotropic medications and an increased risk of suffering from obstructive sleep apnea (OSA) in patients under treatment with psychotropic medication who were hospitalized in Hospital Pasteur (Montevideo, Uruguay) during the July-September 2019 period. With the use of the STOP BANG questionnaire screening method, an elevated risk of OSA was found in 59.4% of the sample, of which 75.6% were male, while 24.4% were female. The elevated risk of OSA was: 54.4% for patients under treatment with a single psychotropic medication and 71.4% for patients under treatment with two psychotropic medications. Of the psychotropic medications the patients were under treatment with, the medications most frequently linked to an elevated OSA risk were antipsychotic medications.